Sarah J. Nelson

Sarah J. Nelson

Auto-generated profile, based on publicly available information

Sarah J. Nelson

Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2004 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
JOJoonmi Oh
Joonmi Oh
RHRoland G. Henry
Roland G. Henry
APAndrea Pirzkall
Andrea Pirzkall
YLYing Lu
Ying Lu
XLXiaojuan Li
Xiaojuan Li
SNSarah J. Nelson
Sarah J. Nelson
Purpose: To investigate the potential value of pre‐external‐beam radiation therapy (XRT) choline‐to‐NAA (N‐acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting survival in newly diagnosed patients with glioblastoma multiforme (GBM).Materials and Methods: Twenty‐eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion‐ and perfusion‐weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI ≥ 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast‐enhancing and T2 regions. The median survival time was compared.Results: A significantly shorter median survival time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter median survival time was also observed for patients with contrast‐enhancing residual disease than for those without the presence of contrast enhancement with marginal significance.Conclusion: The pre‐XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM. J. Magn. Reson. Imaging 2004;19:546–554.

1 October 2002 in Brain and Cognition
Verified
Journal Article
Closed access
DBDiana Blum
Diana Blum
AYAndrew P. Yonelinas
Andrew P. Yonelinas
TLTracy Luks
Tracy Luks
DNDavid Newitt
David Newitt
JOJoonmi Oh
Joonmi Oh
DPDaniel Pelletier
Daniel Pelletier

1 November 1990 in Planta
Verified
Journal Article
Closed access
PDF file
LWLorraine E. Williams
Lorraine E. Williams
SNS. J. Nelson
S. J. Nelson
JHJ. L. Hall
J. L. Hall

1 January 2003 in Journal of Consulting and Clinical Psychology
Verified
Journal Article
Closed access
DMDavid C. Mohr
David C. Mohr
LELucy Epstein
Lucy Epstein
TLTracy L. Luks
Tracy L. Luks
DGDonald Goodkin
Donald Goodkin
DCDarcy Cox
Darcy Cox
SNSarah Nelson
Sarah Nelson
This study examined the effects of brain lesions and neuropsychological impairment on the efficacy of treatment for depression in patients with comorbid diagnoses of multiple sclerosis (MS) and major depressive disorder (MDD). Thirty patients meeting criteria for MS and MDD received 1 of 3 16-week treatments for depression and were followed for 6 months following treatment cessation. T2-weighted magnetic resonance imaging and neuropsychological evaluations were also obtained. End-of-treatment Beck Depression Inventory (BDI; A. T. Beck, C. H. Ward, M. Mendelson, J. Mock, & J. Erbaugh, 1961) results residualized for baseline BDI were related to right temporal periventricular lesion volume (R2=.32, p=.002) and left temporal grey-white junction lesion volume (R2=.19, p=.02) but were not statistically related to lesion volume in any other brain region or to neuropsychological function. BDI results at 6-month follow-up, residualized for end-of-treatment BDI, were predicted by total lesion volume (R2=.22, p=.005), lesion volume in many discrete areas, and neuropsychological functioning (R2=.29, p=.0009). The effect of total lesion volume on 6-month follow-up BDI results was fully mediated by neuropsychological function.

1 December 2017 in Translational Oncology
Verified
Journal Article
Open access
AAAdam Autry
Adam Autry
JPJoanna J. Phillips
Joanna J. Phillips
SMStojan Maleschlijski
Stojan Maleschlijski
RRRitu Roy
Ritu Roy
AMAnnette M. Molinaro
Annette M. Molinaro
SNSarah J. Nelson
Sarah J. Nelson
Although the contrast-enhancing (CE) lesion on T1-weighted MR images is widely used as a surrogate for glioblastoma (GBM), there are also non-enhancing regions of infiltrative tumor within the T2-weighted lesion, which elude radiologic detection. Because non-enhancing GBM (Enh-) challenges clinical patient management as latent disease, this study sought to characterize ex vivo metabolic profiles from Enh- and CE GBM (Enh+) samples, alongside histological and in vivo MR parameters, to assist in defining criteria for estimating total tumor burden. Fifty-six patients with newly diagnosed GBM received a multi-parametric pre-surgical MR examination. Targets for obtaining image-guided tissue samples were defined based on in vivo parameters that were suspicious for tumor. The actual location from where tissue samples were obtained was recorded, and half of each sample was analyzed for histopathology while the other half was scanned using HR-MAS spectroscopy. The Enh+ and Enh- tumor samples demonstrated comparable mitotic activity, but also significant heterogeneity in microvascular morphology. Ex vivo spectroscopic parameters indicated similar levels of total choline and N-acetylaspartate between these contrast-based radiographic subtypes of GBM, and characteristic differences in the levels of myo-inositol, creatine/phosphocreatine, and phosphoethanolamine. Analysis of in vivo parameters at the sample locations were consistent with histological and ex vivo metabolic data. The similarity between ex vivo levels of choline and NAA, and between in vivo levels of choline, NAA and nADC in Enh+ and Enh- tumor, indicate that these parameters can be used in defining non-invasive metrics of total tumor burden for patients with GBM.

21 June 2022 in Pain Reports
Verified
Journal Article
Open access
NKNan Kennedy
Nan Kennedy
SNSarah Nelson
Sarah Nelson
RJRebecca N. Jerome
Rebecca N. Jerome
TETerri L. Edwards
Terri L. Edwards
MSMary Stroud
Mary Stroud
PHPaul A. Harris
Paul A. Harris
Opioid misuse is at a crisis level. In response to this epidemic, the National Institutes of Health has funded $945 million in research through the Helping to End Addiction Long-term (HEAL) Pain Management Initiative, including funding to the Vanderbilt Recruitment Innovation Center (RIC) to strategize methods to catalyze participant recruitment. The RIC, recognizing the challenges presented to clinical researchers in recruiting individuals experiencing pain, conducted a review of evidence in the literature on successful participant recruitment methods for chronic pain trials, in preparation for supporting the HEAL Pain trials. Study design as it affects recruitment was reviewed, with issues such as sufficient sample size, impact of placebo, pain symptom instability, and cohort characterization being identified as problems. Potential solutions found in the literature include targeted electronic health record phenotyping, use of alternative study designs, and greater clinician education and involvement. For retention, the literature reports successful strategies that include maintaining a supportive staff, allowing virtual study visits, and providing treatment flexibility within the trial. Community input on study design to identify potential obstacles to recruitment and retention was found to help investigators avoid pitfalls and enhance trust, especially when recruiting underrepresented minority populations. Our report concludes with a description of generalizable resources the RIC has developed or adapted to enhance recruitment and retention in the HEAL Pain studies. These resources include, among others, a Recruitment and Retention Plan Template, a Competing Trials Tool, and MyCap, a mobile research application that interfaces with Research Electronic Data Capture (REDCap).